Astaxanthin nutraceutical provider AstaReal has taken another step into the consumer market by expanding its D2C portfolio with the addition of Kyolic.
Kyolic is a range of garlic supplements focused on cardiovascular health, which are all extensively researched — with more than 900 scientific publications touting their impact on the body.
The company will roll out Kyolic across the Swedish and Norwegian markets under its name, which is already well-respected in these regions.
This is the second venture AstaReal has made into the consumer market, with the company deciding to take over the distribution rights of Astaxin, its dietary supplement rich in vitamins C, E and astaxanthin, in 2024.
To discuss the AstaReal's decision to move into the consumer health market, how it might benefit the company's B2B operations and why Kyolic, NBR chatted with Peter Ahlm, Head of Marketing & Sales at AstaReal.
Not yet a Subscriber?
This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Nutraceutical Business Review.
Subscribe now Already a subscriber? Sign in here.